Johnson & Johnson's Stelara (ustekinumab) has received its second drubbing in recent weeks in head-to-head studies with rival anti-inflammatories in plaque psoriasis. Novartis says that top-line data from the Phase III CLEAR study show that its new anti-IL17A monoclonal secukinumab (Cosentyx) was better than Stelara in clearing the skin, and it met its primary endpoint.
The data come just a month after Amgen and AstraZeneca's new monoclonal that targets the IL-17 receptor, brodalumab, also beat...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?